Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma
Published: 12 Jun 2020
Views: 97
Dr Katie Kelley - University of California San Francisco, San Francisco, USA
Dr Katie Kelley talks to ecancer in an online interview for the ASCO virtual meeting 2020 about using durvalumab and tremelimumab for the treatment of advanced hepatocellular carcinoma.
She initially gives a thorough description of the trial design and rationale for the four study arms.
Dr Kelley proceeds to detail the results and whether the endpoints were met, and also some interesting outcomes from the biomarker analyses.
She looks forward to new data coming out, including the HIMALAYA trial.
Related Videos
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
30 Jun 2020
Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associate...
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
29 May 2020
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural m...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
7 Oct 2019
PARP inhibitors for metastatic breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
7 Oct 2019
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast can...
Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA
4 Oct 2019
An overview of the latest advances in gastric cancer
Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium
17 Jul 2019
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive pa...
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
18 Apr 2019
ASCO GU 2019 renal highlights
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
14 Feb 2019
